Matthias Löhle

Project description

In 2006, Takahashi and Yamanaka for the first time reported that mouse embryonic and adult fibroblasts acquired the morphology and growth properties of embryonic stem cells after retroviral introduction of four transcription factors, namely Oct4, Sox2, Klf4 and c-Myc. The authors called these cells, which also showed expression of embryonic stem cell marker genes after reprogramming, induced pluripotent stem (iPS) cells. Due to their ability to self-renew and to differentiate into any cell type of the body, iPS cells will presumably become a powerful source for cell replacement therapy in various diseases. In the current project, we are focusing on examining the neuronal differentiation potential of these cells, whose investigation is a major precondition for their future use in neurodegenerative diseases, such as Parkinson’s disease.



Curriculum vitae

Dr. med. Matthias Löhle

Department of Neurology

University Hospital Carl Gustav Carus

Dresden University of Technology

Fetscherstrasse 74

01307 Dresden

Personal data

Date of birth: April 29th, 1977

Place of birth: Jena

Nationality: German

Marital status: Single

Academic qualifications

License to practice medicine: October 22nd, 2002

Friedrich Schiller University Jena

M.D.: May 31st, 2005

Friedrich Schiller University Jena

Thesis title: “The influence of a prenatal glucocorticoid therapy on fetal cerebral blood flow and cerebral autoregulation in different gestational ages.”

Professional experience

2003-2004: Research Scholar for the Department of Obstetrics & Gynecology, New York University, USA and at the Center for the Study of Fetal Programming, University of Wyoming, USA

Supervisor: Prof. Peter Nathanielsz, M.D., Ph.D., Sc.D., FRCOG

2004-2005: Elective period at the Department of Neurology at the “Kantonspital St.Gallen”, St.Gallen, Switzerland.

since 2005: Assistant doctor at the Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.

Member of the Group for Neuroregeneration

Supervisor: Prof. Alexander Storch, M.D., Ph.D.

Clinical specialties: Parkinson’s disease, Huntington’s disease, atypical Parkinson syndromes, tremor, ataxia and dystonia




1) Loehle M, Schwab M, Kadner S, Maner KM, Gilbert JS, Brenna JT, Ford SP, Nathanielsz PW, Nijland MJ. Dose-response effects of betamethasone on maturation of the fetal sheep lung. Am J Obstet Gynecol. 2010 Feb;202(2):186.e1-186.e7.

2) Löhle M, Reichmann H. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci. 2010;289(1-2):104-14.

3) Reichmann H, Schneider C, Löhle M. Non-motor features of Parkinson's disease: depression and dementia. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S87-92.

4) Löhle M, Storch A, Reichmann H. Beyond tremor and rigidity: non-motor features of Parkinson's disease. J Neural Transm. 2009;116(11):1483-92.

5) Wolz M, Kaminsky A, Löhle M, Koch R, Storch A, Reichmann H. Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study. J Neurol. 2009;256(3):488-92.

6) Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24(6):826-32.

7) Löhle M, Storch A. Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2008;9(16):2881-91.

8) Wolz M, Junghanns S, Löhle M, von Kummer R, Storch A. Dystonia associated with hyperintense basal ganglia lesions on T1-weighted brain MRI. Mov Disord. 2008;23(11):1618-9.

9) Löhle M, Schrempf W, Wolz M, Reichmann H, Storch A. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report. Mov Disord. 2008;23(9):1314-6.

10) Frasch MG, Müller T, Wicher C, Weiss C, Löhle M, Schwab K, Schubert H, Nathanielsz PW, Witte OW, Schwab M. Fetal body weight and the development of the control of the cardiovascular system in fetal sheep. J Physiol. 2007;579(Pt3):893-907.

11) Samtani MN, Löhle M, Grant A, Nathanielsz PW, Jusko WJ. Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use. Drug Metab Dispos. 2005;33(8):1124-30.

12) Löhle M, Müller T, Wicher C, Roedel M, Schubert H, Witte OW, Nathanielsz PW, Schwab M. Betamethasone effects on fetal sheep cerebral blood flow are not dependent on maturation of cerebrovascular system and pituitary-adrenal axis. J Physiol. 2005;564(Pt 2):575-88.

13) Müller T, Löhle M, Schubert H, Bauer R, Wicher C, Antonow-Schlorke I, Sliwka U, Nathanielsz PW, Schwab M. Developmental changes in cerebral autoregulatory capacity in the fetal sheep parietal cortex. J Physiol. 2002;539(Pt 3):957-67.